Retatrutide is the unimolecular triple agonist furthest in development and data from phase 2 trials suggests that this may soon become the most potent weight-lowering pharmacotherapy to be licenced
For FDA-approved GLP-1 medications, out-of-pocket cost can vary by insurance coverage, diagnosis, plan design, manufacturer savings-card eligibility, pharmacy, and dose
earlystage companies may still face cashflow constraints
Impaired Akt-mediated suppression of Forkhead box O1 (FOXO1) transcription factors also disrupts cellular homeostasis [7], and Jun N-terminal kinase (JNK) activation promotes insulin resistance and Beta cells (-cell) dysfunction [8]
Both medications have similar digestive side effects, and the better option depends on treatment goals, tolerance, and medical guidance